PE20210401A1 - Composiciones farmaceuticas que comprenden meloxicam - Google Patents
Composiciones farmaceuticas que comprenden meloxicamInfo
- Publication number
- PE20210401A1 PE20210401A1 PE2020002265A PE2020002265A PE20210401A1 PE 20210401 A1 PE20210401 A1 PE 20210401A1 PE 2020002265 A PE2020002265 A PE 2020002265A PE 2020002265 A PE2020002265 A PE 2020002265A PE 20210401 A1 PE20210401 A1 PE 20210401A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical compositions
- compositions including
- meloxicam
- including meloxicam
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
En la presente descripcion se describe una composicion que comprende meloxicam, 400 mg de bicarbonato de sodio y un farmaco triptano tal como rizatriptan, donde dicha composicion tambien puede comprender una ciclodextrina. Estas composiciones pueden administrarse por via oral, por ejemplo, para mejorar la biodisponibilidad, la solubilidad o la farmacocinetica del farmaco para el tratamiento de afecciones tales como el dolor
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862693871P | 2018-07-03 | 2018-07-03 | |
US201962802198P | 2019-02-06 | 2019-02-06 | |
US201962803756P | 2019-02-11 | 2019-02-11 | |
US201962835613P | 2019-04-18 | 2019-04-18 | |
US201962846311P | 2019-05-10 | 2019-05-10 | |
US201962860705P | 2019-06-12 | 2019-06-12 | |
PCT/US2019/040495 WO2020010196A1 (en) | 2018-07-03 | 2019-07-03 | Pharmaceutical compositions comprising meloxicam |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210401A1 true PE20210401A1 (es) | 2021-03-02 |
Family
ID=69059998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020002265A PE20210401A1 (es) | 2018-07-03 | 2019-07-03 | Composiciones farmaceuticas que comprenden meloxicam |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220096490A1 (es) |
EP (1) | EP3817722A4 (es) |
JP (2) | JP7237375B2 (es) |
KR (1) | KR20210027371A (es) |
CN (1) | CN112384198A (es) |
AU (2) | AU2019297360B2 (es) |
BR (1) | BR112020026965A2 (es) |
CA (1) | CA3105476A1 (es) |
CL (1) | CL2020003443A1 (es) |
CO (1) | CO2021000789A2 (es) |
CR (1) | CR20210061A (es) |
IL (1) | IL279442A (es) |
MX (1) | MX2020014128A (es) |
NI (1) | NI202000105A (es) |
PE (1) | PE20210401A1 (es) |
SG (1) | SG11202012376PA (es) |
WO (1) | WO2020010196A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11045549B2 (en) | 2015-02-10 | 2021-06-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11602563B2 (en) | 2015-02-10 | 2023-03-14 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11738085B2 (en) | 2015-02-10 | 2023-08-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10933136B2 (en) | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11607456B2 (en) | 2015-02-10 | 2023-03-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11433078B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11806354B2 (en) | 2017-01-04 | 2023-11-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11617755B2 (en) | 2017-01-04 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11471465B2 (en) | 2017-01-04 | 2022-10-18 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11801250B2 (en) | 2017-01-04 | 2023-10-31 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11433079B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11865117B2 (en) | 2017-06-29 | 2024-01-09 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
US11617756B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11510927B2 (en) | 2017-06-29 | 2022-11-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11759522B2 (en) | 2017-06-29 | 2023-09-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10918722B2 (en) | 2017-06-29 | 2021-02-16 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11617791B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US11185550B2 (en) | 2017-06-29 | 2021-11-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
WO2023225596A1 (en) * | 2022-05-19 | 2023-11-23 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214861A1 (en) * | 2003-03-28 | 2004-10-28 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine |
BRPI0409127A (pt) | 2003-04-11 | 2006-03-28 | Pfizer | combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio |
WO2004110492A2 (en) | 2003-06-06 | 2004-12-23 | Glaxo Group Limited | Composition comprising triptans and nsaids |
AU2005247048B2 (en) | 2004-05-28 | 2007-12-13 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
AU2007310949A1 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
US20090068262A1 (en) * | 2007-04-04 | 2009-03-12 | Ilan Zalit | Rapid dissolution of combination products |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
CN101984960B (zh) * | 2010-10-29 | 2011-10-26 | 四川梓橦宫药业有限公司 | 苯甲酸利扎曲普坦胶囊及其制备方法 |
US9821075B2 (en) * | 2015-02-10 | 2017-11-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
KR102465027B1 (ko) * | 2015-02-10 | 2022-11-09 | 액섬 테라퓨틱스, 인크. | 멜록시캄을 포함하는 약학 조성물 |
US10058614B2 (en) * | 2015-02-10 | 2018-08-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US10471014B2 (en) * | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
-
2019
- 2019-07-03 AU AU2019297360A patent/AU2019297360B2/en active Active
- 2019-07-03 EP EP19830839.7A patent/EP3817722A4/en active Pending
- 2019-07-03 KR KR1020217001263A patent/KR20210027371A/ko active Search and Examination
- 2019-07-03 CN CN201980044810.8A patent/CN112384198A/zh active Pending
- 2019-07-03 CR CR20210061A patent/CR20210061A/es unknown
- 2019-07-03 CA CA3105476A patent/CA3105476A1/en active Pending
- 2019-07-03 JP JP2020573124A patent/JP7237375B2/ja active Active
- 2019-07-03 PE PE2020002265A patent/PE20210401A1/es unknown
- 2019-07-03 BR BR112020026965-4A patent/BR112020026965A2/pt unknown
- 2019-07-03 WO PCT/US2019/040495 patent/WO2020010196A1/en unknown
- 2019-07-03 SG SG11202012376PA patent/SG11202012376PA/en unknown
- 2019-07-03 MX MX2020014128A patent/MX2020014128A/es unknown
-
2020
- 2020-12-14 IL IL279442A patent/IL279442A/en unknown
- 2020-12-29 NI NI202000105A patent/NI202000105A/es unknown
- 2020-12-30 CL CL2020003443A patent/CL2020003443A1/es unknown
-
2021
- 2021-01-25 CO CONC2021/0000789A patent/CO2021000789A2/es unknown
- 2021-12-10 US US17/547,676 patent/US20220096490A1/en not_active Abandoned
-
2022
- 2022-10-17 AU AU2022252856A patent/AU2022252856A1/en active Pending
-
2023
- 2023-02-21 JP JP2023024882A patent/JP7485807B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3817722A4 (en) | 2022-03-23 |
JP2021529759A (ja) | 2021-11-04 |
JP7237375B2 (ja) | 2023-03-13 |
JP2023062134A (ja) | 2023-05-02 |
NI202000105A (es) | 2021-03-23 |
AU2019297360A1 (en) | 2021-01-28 |
CO2021000789A2 (es) | 2021-01-29 |
IL279442A (en) | 2021-01-31 |
CL2020003443A1 (es) | 2021-05-07 |
US20220096490A1 (en) | 2022-03-31 |
CR20210061A (es) | 2021-03-18 |
SG11202012376PA (en) | 2021-01-28 |
JP7485807B2 (ja) | 2024-05-16 |
BR112020026965A2 (pt) | 2021-03-30 |
CN112384198A (zh) | 2021-02-19 |
WO2020010196A1 (en) | 2020-01-09 |
MX2020014128A (es) | 2021-06-18 |
AU2022252856A1 (en) | 2022-11-17 |
CA3105476A1 (en) | 2020-01-09 |
AU2019297360B2 (en) | 2022-07-21 |
KR20210027371A (ko) | 2021-03-10 |
EP3817722A1 (en) | 2021-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
MX2021014509A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
AR070731A1 (es) | Composicion farmaceutica para farmacos poco solubles | |
AR062397A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
PE20061418A1 (es) | Composiciones farmaceuticas de 4-[(ciclopropanocarbonilamino)metil]-2-(2,6-dioxopiperidin-3-il)isoindol-1,3-diona para el tratamiento o prevencion de lupus cutaneo | |
AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
CO2020001887A2 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático | |
ECSP23005057A (es) | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo | |
AR068560A1 (es) | Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroide y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota artritis gotosa y enfermedades relacionadas | |
ECSP21006974A (es) | Composiciones farmacéuticas que comprenden meloxicam | |
RU2018130097A (ru) | Лечение экземы кистей | |
PL425832A1 (pl) | Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera | |
AR067320A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias | |
CO2021006473A2 (es) | Composición farmacéutica que comprende la combinación de un inhibidor selectivo de la ciclooxigenasa 2 y un carbamato derivado de la guaifenesina para el tratamiento del dolor, inflamación y contractura muscular | |
BR112023003572A2 (pt) | Formulação oral sólida de utidelona | |
RU2012123302A (ru) | Лекарственное средство, предупреждающее предрак и рак простаты, фармацевтическая композиция, активный ингредиент фармацевтической композиции и способ химиопрофилактики рака простаты | |
AR118056A2 (es) | Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y uso de las mismas | |
PL429246A1 (pl) | Przeciwbólowo - przeciwzapalna kompozycja farmaceutyczna do stosowania w profilaktyce gorączki i/lub bólu, zwłaszcza do stosowania w stanach zapalnych jamy ustnej i gardła | |
AR121828A1 (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato o solvato de esta |